N-benzyl-5-chloro-1H-indole-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-benzyl-5-chloro-1H-indole-2-carboxamide
• 化学式: C₁₆H₁₃ClN₂O
• mdl: MFCD06775931
• 分子量: 284.745
• InChiKey: YEMVVFFCUOHNBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.062
• 拓扑面积：
  44.9
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-benzyl-5-chloro-1H-indole-2-carboxamide 、 phenyl vinyl selenone 在 potassium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 24.17h， 以55%的产率得到2-benzyl-8-chloro-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one
  参考文献：
  名称：

  A domino approach to pyrazino- indoles and pyrroles using vinyl selenones

  摘要：

  Herein we disclose an efficient and flexible approach to biologically relevant 3,4-dihydropyrazino[1,2-alpha] indol-1(2H)ones and 3,4-dihydropyrrolo[1,2-alpha]pyrazin-1(2H)ones through a domino Michael/intra-molecular nucleophilic substitution pathway using potassium hydroxide in dichloromethane. Variously substituted vinyl selenones and 1H-indole-2-carboxamides or 1H-pyrrole-2-carboxamides have been employed with success in chemo and regio-selective processes. The introduction of an amino acid portion on the amidic function is well tolerated without racemization. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2018.10.044

文献信息

• Indole derivatives for use in medicine
  申请人：IOmet Pharma Ltd.

  公开号：US10167257B2

  公开（公告）日：2019-01-01

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R1, R2, R3, R4, R5, and R7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X1, X2, X3, X4, and X5 are maintained; one or two R6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R6 is an organic group comprising an atom double-bonded to an oxygen atom (preferably a carbonyl group or a sulphonyl group) at an α-, β-, or γ-position to the carbon atom to which the R6 is attached and in which the atom double-bonded to an oxygen atom is also bonded to a hetero-atom.

  本发明提供了一种用于医药的色氨酸-2,3-二氧化酶（TDO）和/或吲哚胺-2,3-二氧化酶（IDO）抑制剂化合物，该化合物包括下式：其中 X1、X2、X3、X4 和 X5 可以相同或不同，且各自独立地选自 C、N 和 O；每个带有虚线的原子可以独立地具有双键或单键，前提是每个原子上的价保持不变；每个 R1、R2、R3、R4、R5 和 R7 可以存在或不存在，可以相同或不同，并且可以选自 H 和取代或未取代的有机基团，条件是存在的此类 R 基团的数目使得 X1、X2、X3、X4 和 X5 的化合价保持不变；可存在一个或两个 R6 基团，它们选自 H 和一个取代或未取代的有机基团，条件是所存在的 R6 基团的数目必须保证它们所连接的碳原子的价保持不变、且至少有一个 R6 是有机基团，该有机基团包含一个与氧原子（最好是羰基或磺酰基）在与 R6 所连接的碳原子的 α-、β- 或 γ- 位置上双键结合的原子，其中与氧原子双键结合的原子还与杂原子结合。
• INDOLE DERIVATIVES FOR USE IN MEDICINE
  申请人：IOmet Pharma Ltd.

  公开号：US20170107178A1

  公开（公告）日：2017-04-20

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X 1 , X 2 , X 3 , X 4 , and X 5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R 1 , R 2 , R 3 , R 4 , R 5 , and R 7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 1 , X 2 , X 3 , X 4 , and X 5 are maintained; one or two R 6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R 6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R 6 is an organic group comprising an atom double-bonded to an oxygen atom (preferably a carbonyl group or a sulphonyl group) at an α-, β-, or γ-position to the carbon atom to which the R 6 is attached and in which the atom double-bonded to an oxygen atom is also bonded to a hetero-atom.